An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics (MESSAGE)

NCT00448630 COMPLETED Results posted

The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.

Details

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status	COMPLETED
Enrolment	328
Start date	Tue Oct 23 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jul 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Schizophrenia
• Metabolic Syndrome X

Interventions

• No intervention

Countries

Turkey (Türkiye)